| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,714 |
1,478 |
$145K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
781 |
752 |
$122K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
550 |
512 |
$82K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
587 |
580 |
$71K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
232 |
231 |
$47K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
687 |
663 |
$29K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
578 |
520 |
$17K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
327 |
298 |
$8K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
381 |
350 |
$8K |
| 80061 |
Lipid panel |
128 |
118 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
139 |
131 |
$1K |
| 86328 |
|
35 |
35 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
72 |
70 |
$850.30 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14 |
14 |
$553.28 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
29 |
15 |
$543.48 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
235 |
227 |
$449.36 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
96 |
90 |
$233.08 |
| 81003 |
|
144 |
137 |
$217.30 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
316 |
302 |
$211.25 |
| 87807 |
|
13 |
13 |
$189.63 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$148.80 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
12 |
12 |
$2.86 |
| 3008F |
|
1,098 |
933 |
$0.00 |